Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
MGNX 
MacroGenics Inc (MGNX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: MGNX (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
9 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $4.2
1 Year Target Price $4.2
| 2 | Strong Buy |
| 1 | Buy |
| 6 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 132.95% | Avg. Invested days 52 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 75.08M USD | Price to earnings Ratio - | 1Y Target Price 4.2 |
Price to earnings Ratio - | 1Y Target Price 4.2 | ||
Volume (30-day avg) 9 | Beta 1.63 | 52 Weeks Range 0.99 - 5.77 | Updated Date 06/29/2025 |
52 Weeks Range 0.99 - 5.77 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.88 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -36.23% | Operating Margin (TTM) -323.11% |
Management Effectiveness
Return on Assets (TTM) -26.29% | Return on Equity (TTM) -60.25% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -41597516 | Price to Sales(TTM) 0.49 |
Enterprise Value -41597516 | Price to Sales(TTM) 0.49 | ||
Enterprise Value to Revenue 2.69 | Enterprise Value to EBITDA -1.54 | Shares Outstanding 63090300 | Shares Floating 51666558 |
Shares Outstanding 63090300 | Shares Floating 51666558 | ||
Percent Insiders 3.01 | Percent Institutions 73.84 |
Analyst Ratings
Rating 3 | Target Price 4.2 | Buy 1 | Strong Buy 2 |
Buy 1 | Strong Buy 2 | ||
Hold 6 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
MacroGenics Inc
Company Overview
History and Background
MacroGenics, Inc. was founded in 2000. It is a biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The company has evolved from a research-focused organization to one with marketed products and a robust pipeline.
Core Business Areas
- Oncology: Focused on developing immunotherapies for various cancers, including those that are difficult to treat.
- Autoimmune Diseases: Developing therapies targeting autoimmune disorders.
Leadership and Structure
The leadership team consists of experienced executives in biotechnology and pharmaceuticals. The organizational structure includes research, development, clinical, and commercial divisions.
Top Products and Market Share
Key Offerings
- Margenza (margetuximab-cmkb): Margenza is an HER2-positive breast cancer therapy. Revenue and market share data fluctuate, impacted by ongoing clinical trials and competition from drugs like Herceptin (Roche), Perjeta (Roche), and Kadcyla (Roche). Competition is intense among these major players
- Vobramitamab duocarmazine: An ADC in phase I testing for various cancers. There is no market share yet. Competitors include companies developing ADCs such as Seagen, ImmunoGen, and Daiichi Sankyo.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and rapidly evolving, particularly in oncology and immunotherapy. There is increasing demand for innovative cancer therapies and autoimmune treatments.
Positioning
MacroGenics is positioned as an innovator in antibody-based therapies. Its competitive advantage lies in its proprietary DART and TRIDENT platforms.
Total Addressable Market (TAM)
The TAM for oncology and autoimmune therapeutics is estimated to be in the hundreds of billions of dollars. MacroGenics aims to capture a portion of this market through its innovative therapies.
Upturn SWOT Analysis
Strengths
- Proprietary DART and TRIDENT platforms
- Strong pipeline of antibody-based therapeutics
- Approved product (Margenza) generating revenue
- Experienced management team
Weaknesses
- Reliance on successful clinical trials
- Competition from larger pharmaceutical companies
- Limited commercial infrastructure compared to major players
- History of Net Losses
Opportunities
- Expansion of Margenza's market share
- Successful clinical trial outcomes for pipeline candidates
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established therapies
- Patent expirations
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- Roche Holding AG (RHHBY)
- Seagen Inc. (SGEN)
- ImmunoGen, Inc. (IMGN)
Competitive Landscape
MacroGenics faces stiff competition from larger, more established pharmaceutical companies with greater resources. Its strengths lie in its innovative technology platforms and targeted therapies.
Growth Trajectory and Initiatives
Historical Growth: MacroGenics's historical growth has been characterized by significant investment in research and development, resulting in a growing product pipeline and eventual commercialization of Margenza.
Future Projections: Future growth is dependent on successful clinical trials, regulatory approvals, and market adoption of its pipeline products. Analyst estimates vary widely based on these factors.
Recent Initiatives: Recent initiatives include expanding the clinical development of its pipeline assets, pursuing partnerships for commercialization, and advancing its DART and TRIDENT platforms.
Summary
MacroGenics is a clinical-stage biopharmaceutical company that has made progress in oncology and autoimmune diseases. The company's novel platforms are promising. Future success hinges on advancing its pipeline through successful clinical trials and commercialization. While the company has net losses, it's cash on hand seems sufficient.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Financial data is based on estimates and historical information.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About MacroGenics Inc
Exchange NASDAQ | Headquaters Rockville, MD, United States | ||
IPO Launch date 2013-10-10 | President, CEO & Director Dr. Scott Koenig M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 341 | Website https://www.macrogenics.com |
Full time employees 341 | Website https://www.macrogenics.com | ||
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule for the treatment of solid tumors, which is in preclinical trials. It is also developing next generation T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.